During the silent period, Investor Relations does not arrange any meetings with the press, media, investors, analysts or other capital market players. Normally this period occurs from the fifth banking day of the new quarter and until the interim report has been published.

Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no . About Targovax. Activating the patient's immune system to fight cancer

The quarterly report and presentation are also available at the website www.targovax.com. For further information, please contact: Renate Birkeli , Investor Relations An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today Kim Sutton Golodetz - LHA Investor Relations (US) OSLO, Norway, Feb. 11, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777 About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock The board of directors of Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") has resolved to increase the share capital of the Company following the completion of an exercise period for vested share options under the Company's long-term incentive program for employees. The exercise period for the LTI program commenced on 19 February 2021 at 10:00 hours (CET) and ended on 1 March 2021 at 10 OSLO, Norway, Feb. 11, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777 About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777 About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock OSLO, Feb. 18, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets

Investor Relations Manager Tel: +49 172 7512480 carlo.beck@fortum.com. Back to top . You are here: Fortum Investors In focus Investor Relations Share. Share price Dividend Capital structure Share Buy-Back Indices Key indicators Shareholder structure Basic share information Bonds. Allianz Bonds Rating Announcements.

2021-02-15 TARGOVAX ASA : News, information and stories for TARGOVAX ASA | Oslo Bors: TRVX | Oslo Bors 2018-11-28 2018-09-13 Targovax granted US Patent for ONCOS-102 in combination with checkpoint inhibitors; 8.3.2021 07.00 · Oslo Børs TRVX: Targovax to present and attend at upcoming investor and scientific conferences; 8.3.2021 07.00 · Cision Targovax to present and attend at upcoming investor and scientific conferences OSLO, Norway, Oct. 19, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces OSLO, Norway, Feb. 14, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to targ On 14 March 2018, the board of directors of Targovax ASA approved the company's financial statements for 2017, which will be dealt with by the Company's annual Investor Relations Phone: +47-922-61-624 Email: renate.birkeli@targovax.com . Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47-9300-1773 Email: andreas.tinglum Investor relations. The ironSource story.

An online presentation by Targovax's management to investors, Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777.

Access everything you need as a current or potential shareholder, from share price information and results to recent news and announcements. Learn more.

2021-02-15

The board of directors of Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") has resolved to increase the share capital of the Company following the completion of an exercise period for vested share options under the Company's long-term incentive program for employees. The exercise period for the LTI program commenced on 19 February 2021 at 10:00 hours (CET) and ended on 1 March 2021 at 10

Targovax to present at upcoming investor conferences Oslo, Norway, 14 November 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences: 2017-11-14 · Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. 2018-03-15 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Targovax Shareholders. 314 likes. This is a page for shareholders in Targovax (TRVX at OBX).